Quantcast

Latest Alkaloids Stories

2010-03-08 07:00:00

SOUTH SAN FRANCISCO, Calif., March 8 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009. "Picoplatin's value proposition rests on establishing it as the preferred platinum," said Ronald A. Martell, chief executive officer of Poniard. "With nearly 1,100 patients treated in clinical trials to date, picoplatin...

2010-03-05 13:45:00

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company's Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster Session today at...

2010-02-17 07:00:00

PRINCETON, N.J., Feb. 17 /PRNewswire/ -- Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology. The agreement is part of the NCI's Advanced Technology Partnerships Initiative, which aims to accelerate the delivery of new products to...

2010-01-26 15:02:04

Proteomics study reveals a protein that, when suppressed, makes cancers more susceptible to chemotherapy Taxanes, a group of cancer drugs that includes paclitaxel (Taxol®) and docetaxel (Taxotere®), have become front-line therapy for a variety of metastatic cancers. But as with many chemotherapy agents, resistance can develop, a frequent problem in breast, ovarian, prostate and other cancers. Now, cancer researchers at Children's Hospital Boston report a...

2009-12-23 10:27:00

PHILADELPHIA, Dec. 23 /PRNewswire/ -- URL Pharma, Inc. today announced the launch of the Colcrys® (colchicine, USP) Patient Assistance Program, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This program reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment...

2009-12-21 06:45:00

ROCHESTER, N.Y., Dec. 21 /PRNewswire/ -- Clerisy Corp. announces the launch of Nasal SoftStrips(TM), a revolutionary new product designed to administer over the counter (OTC) medicants or aromatic blends of essential oils through a convenient nasal strip. Doctor-developed Nasal SoftStrips(TM) are a patented and FDA market-approved medical delivery device designed to provide consumers with a safe, effective and all-natural means to improve and manage their health and well being. Clerisy...

2009-12-11 15:45:00

WAYNE, N.J. and EMERYVILLE, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). The first of these studies evaluated Nexavar® (sorafenib) tablets in combination with chemotherapy agent capecitabine and the...

2009-12-08 12:46:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Bulk Paclitaxel - A Global Update of Market Trends & Opportunities http://www.reportlinker.com/p0164226/Bulk-Paclitaxel---A-Global-Update-of-Market-Trends--Opportunities.html World bulk paclitaxel market stands enthused by the effervescent levels of research and development. With market participants injecting resources into developing unique paclitaxel...

2009-12-01 07:00:00

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that a new, recently completed preclinical study has affirmed the bioequivalence and comparable toxicity of ANX-514 and Taxotere® (docetaxel). Shin Poong Pharmaceuticals, ADVENTRX's partner for ANX-514 in South Korea, independently conducted the study and data analysis. "Our independent confirmation of the bioequivalence and comparable overall safety of ANX-514...

a8c4d21e162798cab70e99b6d6e137961
2009-11-24 09:53:22

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumor cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer. This research was conducted by Ana Rosa Rama Ballesteros, from the Department of Anatomy and Human Embryology at the University...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related